On November 2, 2021 Novo Nordisk reported that initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules") (Press release, Novo Nordisk, NOV 2, 2021, View Source [SID1234594203]). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the programme initiated 4 August 2021, Novo Nordisk has repurchased B shares for an amount up to DKK 3.3 billion in the period from 5 August 2021 to 1 November 2021. The programme is now concluded.

Since the announcement 25 October 2021, the following transactions have been made:

With the transactions stated above, Novo Nordisk owns a total of 22,633,347 B shares of DKK 0.20 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12- month period beginning 3 February 2021. As of 1 November 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 23,826,181 B shares at an average share price of DKK 511.47 per B share equal to a transaction value of DKK 12,186,313,644.